98%
921
2 minutes
20
Background: Atopic dermatitis (AD) has long been regarded as a primarily pediatric disease. However, there is growing evidence for a high rate of adult-onset AD. We aimed to characterize factors associated with adult-onset versus childhood-onset AD and controls.
Methods: We analyzed cross-sectional data of the CK-CARE-ProRaD cohorts Bonn, Augsburg, Davos, Zürich of 736 adult patients stratified by age of AD onset (childhood-onset <18 years: 76.4% (subsets: 0 to 2; ≥2 to 6; ≥7 to 11; ≥12 to 18); adult-onset ≥18 years: 23.6% (subsets: ≥18 to 40; ≥41 to 60; ≥61) and 167 controls (91 atopic, 76 non-atopic)).
Results: We identified active smoking to be associated with adult-onset AD versus controls (adjusted Odds Ratio (aOR) = 5.54 [95% Confidence Interval: 1.06-29.01] vs. controls , aOR = 4.03 [1.20-13.45] vs. controls ). Conjunctivitis showed a negative association versus controls (aOR = 0.36 [0.14-0.91]). Food allergy (aOR = 2.93 [1.44-5.96]), maternal food allergy (aOR = 9.43 [1.10-80.95]), palmar hyperlinearity (aOR = 2.11 [1.05-4.25]), and academic background (aOR = 2.14 [1.00-4.54]) increased the odds of childhood-onset AD versus controls . Shared AD-associated factors were maternal AD (4-34x), increased IgE (2-20x), atopic stigmata (2-3x) with varying effect sizes depending on AD onset and control group. Patients with adult-compared to childhood-onset had doubled odds of allergic rhinitis (aOR = 2.15 [1.12-4.13]), but reduced odds to feature multiple (3-4) atopic comorbidities (aOR = 0.34 [0.14-0.84]). Adult-onset AD, particularly onset ≥61 years, grouped mainly in clusters with low contributions of personal and familial atopy and high frequencies of physical inactivity, childhood-onset AD, particularly infant-onset, mainly in "high-atopic"-clusters.
Conclusions: The identified associated factors suggest partly varying endo- and exogeneous mechanisms underlying adult-onset versus childhood-onset AD. Our findings might contribute to better assessment of the individual risk to develop AD throughout life and encourage prevention by non-smoking and physical activity as modifiable lifestyle factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.15721 | DOI Listing |
J Invest Dermatol
September 2025
Department of Dermatology, Keck School of Medicine of University of South California, Los Angeles, California, USA; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Electronic address:
This review examines the roles of galectins, a family of animal lectins, in inflammatory skin diseases, focusing on their involvement in the pathogenesis of psoriasis, atopic dermatitis, contact dermatitis, and common autoimmune diseases. We highlight the differential expression of galectins in lesional skin and their correlation with inflammatory mediators. In addition, we summarize the functions and mechanisms of action of endogenous galectins, as revealed through studies of genetically engineered cell lines and experimental animals.
View Article and Find Full Text PDFJ Invest Dermatol
September 2025
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Sibel Health, Chicago, Illinois, USA; Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois, USA. Electronic address:
The integration of wearable medical devices and digital health technologies (DHTs) in health care has grown significantly during the past 2 decades, particularly in dermatology, in which objective measurement of symptoms such as itch remains challenging. This review examines the evolution of DHTs in dermatology, focusing on the validation frameworks necessary for their implementation in clinical trials and research. We discuss the key stages of validation: hardware validation to ensure device reliability, analytical validation to transform raw sensor data into meaningful metrics, and clinical validation to demonstrate utility in specific patient populations.
View Article and Find Full Text PDFClin Exp Dermatol
September 2025
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Sleep
September 2025
Instituto do Sono, Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil.
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDF